A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors
Paused · Phase 1
Conditions studied: Neoplasms
In brief
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5 FU in subjects with refractory solid tumors.
Key facts
- Study ID
- NCT00264472
- Run by
- Adherex Technologies, Inc.
- People needed
- 60
- Starts
- 2006-01-01
- Last updated by the study team
- 2008-12-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Signed written informed consent
- > or = 18 years of age
- Advanced or metastatic solid tumors:
- Part 1: Histologically proven advanced or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists
- Part 2: Histologically proven advanced and/or metastatic solid tumor of one of the following 6 histologies, that is refractory to standard curative therapy or for which no curative therapy exists: HCC, NSCLC, gastric cancer, cervical cancer, prostate cancer, and breast cancer
- Radiologically documented measurable or evaluable (non-measurable) disease
- Adequate performance status and organ function, as evidenced by hematologic and biochemical blood testing
- Willing to not receive fluoropyrimidine containing chemotherapy for 8 weeks after the last dose of ADH300004 in this study
You may not qualify if…
- Cytotoxic chemotherapy, radiotherapy, or investigational drug within 28 days prior to study entry
- Non-cytotoxic cancer therapy within 14 days prior to study entry
- Portal hypertension with bleeding esophageal or gastric varices within the past 3 months
- Ascites that is refractory to conservative management
- Inability to take oral medication
- Active peptic ulcer disease
- Known hypersensitivity to 5-FU or ADH300004
- Stroke, major surgery, or other major tissue injury within 30 days before study entry
Where it is running
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.